Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SBB in connection with a directed share issue
Mandate

Vinge has advised SBB in connection with a directed share issue

November 24, 2021 Capital Markets and Public M&A

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with a directed share issue, whereby SBB receives proceeds of approximately MSEK 500.


The subscription price amounts to SEK 70 per Class B common share, which corresponds to a premium of approximately 3.95 percent compared with the closing price for the Class B common share prior to the issue. The new share issue was directed to Gösta Welandson with related parties as well as Wallenstam AB.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Anna Svensson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025